FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895074875> ?p ?o ?g. }

• W2895074875 endingPage "331" @default.
• W2895074875 startingPage "317" @default.
• W2895074875 abstract "Background/Aims: Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase that mediates cell cycle regulation and metabolism. Mounting evidence has indicated that PP2A inhibition exhibits considerable anticancer potency in multiple types of human cancers. However, the efficacy of PP2A inhibition remains unexplored in mucoepidermoid carcinoma (MEC), especially in locally advanced and metastatic cases with limited systemic treatment. In this study, we demonstrated the therapeutic potency of LB100 in mucoepidermoid carcinoma. Methods: In this study, the expression of PP2A was evaluated using immunohistochemical (IHC) staining. The effects associated with LB100 alone and in combination with cisplatin for the treatment of mucoepidermoid carcinoma were investigated both in vitro, regarding metabolism, proliferation, and migration, and in vivo in a mucoepidermoid carcinoma xenograft model. In addition, with LB100 treatment and in response to an insulin stimulus, the expression levels and phosphorylation levels of targets in the PI3K-AKT pathway were determined using western blot analysis and immunoblotting. Results: The expression of protein phosphatase 2A was significantly upregulated in the clinical specimens of high-grade MECs compared with those of low-/medium-grade MECs and normal controls. In this article, we report that a small molecule PP2A inhibitor, LB100, decreased cellular viability and glycolytic activity and induced G2/M cell cycle arrest. Importantly, LB100 enhanced the efficacy of cisplatin in mucoepidermoid carcinoma cells both in vitro and in vivo. PP2A inhibition by LB100 increased the phosphorylation of insulin receptor substrate 1(IRS-1) on serine residues, downregulated the expression of phosphatidylinositol 3-kinase (PI3K) p110 alpha subunit and dephosphorylated AKT at Ser473 and Thr308 in mucoepidermoid carcinoma cells in response to insulin stimulus. Conclusion: These results highlight the translational potential of PP2A inhibition to synergize with cisplatin in mucoepidermoid carcinoma treatment." @default.
• W2895074875 created "2018-10-12" @default.
• W2895074875 creator A5001268974 @default.
• W2895074875 creator A5010082489 @default.
• W2895074875 creator A5015636491 @default.
• W2895074875 creator A5023401890 @default.
• W2895074875 creator A5024315850 @default.
• W2895074875 creator A5026984704 @default.
• W2895074875 creator A5033034900 @default.
• W2895074875 creator A5035465997 @default.
• W2895074875 creator A5041570229 @default.
• W2895074875 creator A5042897178 @default.
• W2895074875 creator A5044756293 @default.
• W2895074875 creator A5058160530 @default.
• W2895074875 creator A5061801664 @default.
• W2895074875 creator A5063992506 @default.
• W2895074875 date "2018-01-01" @default.
• W2895074875 modified "2023-09-30" @default.
• W2895074875 title "Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus" @default.
• W2895074875 cites W158597112 @default.
• W2895074875 cites W1606775748 @default.
• W2895074875 cites W1974043363 @default.
• W2895074875 cites W1977047056 @default.
• W2895074875 cites W1987474302 @default.
• W2895074875 cites W1997048738 @default.
• W2895074875 cites W2017958579 @default.
• W2895074875 cites W2024898443 @default.
• W2895074875 cites W2029580240 @default.
• W2895074875 cites W2029763476 @default.
• W2895074875 cites W2031269916 @default.
• W2895074875 cites W2044038229 @default.
• W2895074875 cites W2050060913 @default.
• W2895074875 cites W2053720051 @default.
• W2895074875 cites W2060026498 @default.
• W2895074875 cites W2065917602 @default.
• W2895074875 cites W2070165953 @default.
• W2895074875 cites W2077536394 @default.
• W2895074875 cites W2083806035 @default.
• W2895074875 cites W2087670396 @default.
• W2895074875 cites W2094079572 @default.
• W2895074875 cites W2100411666 @default.
• W2895074875 cites W2104389725 @default.
• W2895074875 cites W2110054586 @default.
• W2895074875 cites W2117263216 @default.
• W2895074875 cites W2122809300 @default.
• W2895074875 cites W2130326478 @default.
• W2895074875 cites W2132653172 @default.
• W2895074875 cites W2137786893 @default.
• W2895074875 cites W2139191784 @default.
• W2895074875 cites W2139337472 @default.
• W2895074875 cites W2143317528 @default.
• W2895074875 cites W2162127904 @default.
• W2895074875 cites W2169144617 @default.
• W2895074875 cites W2169396440 @default.
• W2895074875 cites W2270966298 @default.
• W2895074875 cites W2301336892 @default.
• W2895074875 cites W2561714923 @default.
• W2895074875 cites W2771057255 @default.
• W2895074875 cites W2772173460 @default.
• W2895074875 cites W2787506206 @default.
• W2895074875 cites W2950369680 @default.
• W2895074875 doi "https://doi.org/10.1159/000494008" @default.
• W2895074875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8114738" @default.
• W2895074875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282066" @default.
• W2895074875 hasPublicationYear "2018" @default.
• W2895074875 type Work @default.
• W2895074875 sameAs 2895074875 @default.
• W2895074875 citedByCount "12" @default.
• W2895074875 countsByYear W28950748752019 @default.
• W2895074875 countsByYear W28950748752020 @default.
• W2895074875 countsByYear W28950748752021 @default.
• W2895074875 countsByYear W28950748752022 @default.
• W2895074875 countsByYear W28950748752023 @default.
• W2895074875 crossrefType "journal-article" @default.
• W2895074875 hasAuthorship W2895074875A5001268974 @default.
• W2895074875 hasAuthorship W2895074875A5010082489 @default.
• W2895074875 hasAuthorship W2895074875A5015636491 @default.
• W2895074875 hasAuthorship W2895074875A5023401890 @default.
• W2895074875 hasAuthorship W2895074875A5024315850 @default.
• W2895074875 hasAuthorship W2895074875A5026984704 @default.
• W2895074875 hasAuthorship W2895074875A5033034900 @default.
• W2895074875 hasAuthorship W2895074875A5035465997 @default.
• W2895074875 hasAuthorship W2895074875A5041570229 @default.
• W2895074875 hasAuthorship W2895074875A5042897178 @default.
• W2895074875 hasAuthorship W2895074875A5044756293 @default.
• W2895074875 hasAuthorship W2895074875A5058160530 @default.
• W2895074875 hasAuthorship W2895074875A5061801664 @default.
• W2895074875 hasAuthorship W2895074875A5063992506 @default.
• W2895074875 hasBestOaLocation W28950748751 @default.
• W2895074875 hasConcept C11960822 @default.
• W2895074875 hasConcept C126322002 @default.
• W2895074875 hasConcept C134018914 @default.
• W2895074875 hasConcept C178666793 @default.
• W2895074875 hasConcept C184235292 @default.
• W2895074875 hasConcept C185592680 @default.
• W2895074875 hasConcept C2778937882 @default.
• W2895074875 hasConcept C2779408958 @default.
• W2895074875 hasConcept C2780859518 @default.

• next